
201 - 500 employees
Founded 2017
🧬 Biotechnology
💊 Pharmaceuticals
🏥 Healthcare
💰 $125M Post-IPO Equity - Stoke Therapeutics on 2024-03
Biotechnology • Pharmaceuticals • Healthcare
Stoke Therapeutics is a biotechnology company developing RNA-based therapeutics that increase protein production from a patient’s own genes to treat rare genetic diseases. Its TANGO (Targeted Augmentation of Nuclear Gene Output) platform uses antisense oligonucleotides to upregulate gene expression in haploinsufficiency disorders. Lead programs include STK‑001, an antisense therapy in development for Dravet syndrome (SCN1A haploinsufficiency), and other programs focused on genetic neurology and rare disease indications.
🕒 July 29
Improve your chances of getting an interview by checking your resume score before you apply.

201 - 500 employees
Founded 2017
🧬 Biotechnology
💊 Pharmaceuticals
🏥 Healthcare
💰 $125M Post-IPO Equity - Stoke Therapeutics on 2024-03
Biotechnology • Pharmaceuticals • Healthcare
Stoke Therapeutics is a biotechnology company developing RNA-based therapeutics that increase protein production from a patient’s own genes to treat rare genetic diseases. Its TANGO (Targeted Augmentation of Nuclear Gene Output) platform uses antisense oligonucleotides to upregulate gene expression in haploinsufficiency disorders. Lead programs include STK‑001, an antisense therapy in development for Dravet syndrome (SCN1A haploinsufficiency), and other programs focused on genetic neurology and rare disease indications.
• Develop and execute pre-launch and launch-phase access strategies across Medicaid FFS and Managed Medicaid, establishing Stoke’s credibility with state agencies ahead of FDA approval. • Serve as Stoke’s primary relationship owner and strategic point of contact across state Medicaid pharmacy and medical directors, DUR/P&T board members, and Managed Medicaid MCO leaders in priority states. • Maintain a deep understanding of account-level policies, state drug review processes, competitive dynamics, decision timelines, and state priorities impacting access. • Develop multi-year state Medicaid access plans that anticipate policy shifts, IRA pricing dynamics, and competitive changes, balancing state-by-state tactical execution with a national access strategy. • Proactively engage state Medicaid medical and pharmacy directors to secure informal billing guidance, coverage letters, or favorable fee-for-service payment determinations ahead of a permanent J code assignment. • Monitor AMP-based reimbursement benchmarks, Medicaid Upper Payment Limits (UPLs), and state-specific drug fee schedules to provide payers with accurate, transparent pricing narratives that support appropriate reimbursement under the medical benefit. • Monitor federal and state Medicaid policy developments—including CMS guidance, CMCS informational bulletins, state plan amendments (SPAs), and 1115/1915 waiver activity—and translate implications for brand access strategy. • Educate government payers on clinical and economic value in frameworks meaningful to state Medicaid budget and policy decision-makers. • Educate Stoke’s patient services and field reimbursement teams on navigating the miscellaneous J code environment at launch, including NDC crosswalk requirements and Medicaid-specific billing procedures. • Serve as the internal subject-matter expert on Medicaid reimbursement dynamics for medical benefit products carrying a miscellaneous J code (J3490/J3590) pending assignment of a permanent, product-specific code. • Lead cross-functional collaboration with Policy, Advocacy, HEOR, Reimbursement, Trade & Distribution, and Marketing partners to advance access goals and account-level execution. • Coordinate pull-through activities with Stoke’s field teams, patient services, and reimbursement teams to ensure coverage decisions translate to patient access. • Synthesize complex CMS guidance, state legislative changes, and IRA pricing developments into clear, actionable implications for the business, communicating effectively from field teams to executive leadership. • Engage authentically with the Dravet syndrome patient and caregiver community and incorporate community insights into government payer engagement in a compelling and compliant manner. • Conduct all government account engagements in full compliance with company SOPs, OIG guidelines, PhRMA Code, the Anti-Kickback Statute, and applicable federal and state Medicaid regulations. • Navigate the unique complexity of a first-in-class disease-modifying ASO therapy with no established Medicaid coverage precedent, finding creative and compliant paths to access.
• Bachelor’s degree required; advanced degree (MBA, PharmD, MPH) strongly preferred. • 15+ years in pharma/biotech; minimum 8 years in government or Medicaid payer account management. • Proven track record of achieving positive formulary and coverage outcomes for high-cost rare or specialty products in state Medicaid programs. • Pre-launch government payer strategy experience—not just maintenance of established access. • Proven ability to navigate and support medical benefit policy creation with Medicaid accounts. • Hands-on experience navigating the miscellaneous J code environment (J3490/J3590) within Medicaid, including payer education on NDC crosswalk requirements, claims-level billing guidance, and coordination with FRMs and specialty distribution in a Medicaid context. • Rare pediatric or rare neurological disease product launch experience; CNS or epilepsy payer experience a significant differentiator. • Familiarity with 340B program intersections for rare disease products and duplicate discount compliance. • Experience navigating Medicaid disability transition pathways (SSI/SSDI) for pediatric-onset neurological disease populations. • Experience at a company building its commercial infrastructure for the first time—startup or early commercial-stage biotech.
• medical, dental and vision insurance • life insurance • long- and short-term disability insurance • paid parental leave • a 401K plan with company match • unlimited vacation time • tuition assistance • participation in our Employee Stock Purchase Program (ESPP)
Apply Now🕒 July 29
Electrical Associate Director leading design activities and overseeing staffing and capacity planning at DLB Associates. Driving organizational development and continuous improvement in engineering processes.
🕒 July 29
Division Associate Director leading engineering operations for DLB Associates, an engineering and consulting firm serving data centers and advanced infrastructure. Driving strategy, client programs, staffing, business development, and digital transformation across MEP consulting sectors.
🕒 July 29
Associate Director of BIM overseeing electrical design and BIM operations for DLB Associates. Leading strategic direction, quality assurance, and execution within all mechanical BIM operations.
🕒 July 29
51 - 200
Associate Director overseeing analytical development and quality control for Kailera's therapies. Collaborating cross-functionally to ensure drug development and manufacturing alignment with regulatory requirements.
🇺🇸 United States – Remote
💵 $155k - $190k / year
🔥 Funding within the last year
💰 $600M Series B - Kailera Therapeutics on 2025-10
⏰ Full Time
🟠 Senior
👔 Director
🕒 July 28
Associate Director for Government Affairs at Travere Therapeutics, driving policy strategies for rare disease treatments. Responsible for strategic leadership and stakeholder engagement in healthcare policy.